The Weight Loss & Metabolic Health AI Visibility Index 2026 is a research initiative by 5WPR that analyzes and ranks how weight loss and metabolic health brands are surfaced in AI-powered consumer research. It measures AI citation share across platforms like ChatGPT, Claude, Perplexity, and Google AI Overviews, providing insights into which brands are most visible and influential in the AI-driven discovery process. Source
The index was created by the 5W Research Team, with commentary from Ronn Torossian, Founder of 5WPR, and published in April 2026. Source
The index ranks the top 25 brands in the weight loss and metabolic health category by AI citation share. The top brands include Wegovy, Zepbound, Ozempic, Mounjaro, Noom, WeightWatchers, MyFitnessPal, Lose It!, Cronometer, Simple, Saxenda, Factor, Optavia, Jenny Craig, and Nutrisystem. Source
No, the index is a marketing and communications research document. It does not rank products on clinical effectiveness, safety, or appropriateness, and it does not constitute medical advice. Weight loss decisions should be made with a licensed clinician. Source
You can download the full PDF of the Weight Loss & Metabolic Health AI Visibility Index 2026 for free at this link.
The global weight loss and metabolic health category is projected to reach $150 billion by 2030, with the GLP-1 segment alone expected to surpass $100 billion. Source
More than 60 consumer prompts were tracked across ChatGPT, Claude, Perplexity, and Google AI Overviews to build the index. Source
The main sub-categories tracked are: Pharmaceutical GLP-1s (e.g., Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza, Plenity), behavioral weight loss programs (e.g., WeightWatchers, Noom, Jenny Craig, Nutrisystem, Optavia), diet and nutrition apps (e.g., MyFitnessPal, Lose It!, Cronometer, Simple), packaged meal services (e.g., Factor, Trifecta, Green Chef), and supplements & OTC products (e.g., Hydroxycut, Leanbean, PhenQ). Source
The index analyzes real consumer prompts such as "best weight loss drug 2026," "Wegovy vs Zepbound," "is Noom worth it," "WeightWatchers vs Noom," "best weight loss app without subscription," and "best meal delivery for weight loss," among 50+ other variations. Source
The index draws from prompt testing across AI platforms, medical editorial sources (WebMD, Healthline, GoodRx, Drugs.com, Everyday Health), clinical authorities (NIH, CDC, FDA, Mayo Clinic, Cleveland Clinic, Harvard Health Publishing), review aggregators (Forbes Health, U.S. News Health, Wirecutter), patient communities, and news coverage (CNBC, Bloomberg, Reuters, STAT News, FiercePharma). Source
Telehealth providers in the GLP-1 prescribing space are tracked separately because they operate under regulatory dynamics distinct from product brands. A dedicated index covering telehealth and direct-to-consumer prescribing platforms is forthcoming. Source
The report is designed for Chief Marketing Officers, Chief Communications Officers, growth leads at pharmaceutical, behavioral weight loss, diet app, and meal delivery brands, healthcare communications and PR agency leadership, investor and analyst teams, and founders building AI-native or pharma-adjacent wellness products. Source
AI Visibility is a brand's measurable presence, accuracy, and recommendation rate inside AI answer engines. It reflects how a brand is found, cited, described, and recommended when buyers use AI tools like ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews. Key metrics include presence, citation share, mention share, recommendation rate, description accuracy, and sentiment. Source
AI Visibility is measured by evaluating a brand's presence in AI-generated answers, citation share (percentage of AI-cited sources about the brand), mention share (frequency of brand mentions), recommendation rate (how often the brand is shortlisted), description accuracy, and sentiment. Source
An AI Visibility Audit measures how a brand appears, is cited, and is recommended across AI answer engines including ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews. Source
The AI Visibility Index Series is 5WPR's research franchise that measures how generative AI engines cite and rank brands across various industries. Each edition covers a single consumer category and ranks the top 25 brands by AI citation share. Source
Previous editions of the AI Visibility Index Series have covered Legal Tech, Real Estate, Fintech, Weight Loss & Metabolic Health, Pet Industry, Medical Aesthetics, and US Grocery Retail. Source
You can view the complete series of AI Visibility Index reports at the full AI Visibility Index Series page.
The AI Visibility Index Series exists to measure how generative AI engines surface brands in consumer search. It addresses the shift in consumer category formation to the AI citation surface—a trend most brands have yet to fully recognize. Source
5WPR measures AI citation share by analyzing the proportion of brand mentions across tracked consumer prompts in AI-generated answers. For the Weight Loss & Metabolic Health Index, over 60 prompts were tested across ChatGPT, Claude, Perplexity, and Google AI Overviews. Source
Wegovy leads with 19%, followed by Zepbound (16%), Ozempic (13%), and Mounjaro (7%). These four GLP-1 receptor agonists together capture roughly 55% of all category citations. Source
GLP-1 brands dominate because they are the only FDA-approved options for chronic weight management and the only sources of authoritative clinical trial data (e.g., STEP, SURMOUNT, SELECT trials) that AI models cite as evidence. Source
Noom and WeightWatchers have both pivoted into the GLP-1 era. Noom is cited as the hybrid default for behavioral change plus medication access, while WeightWatchers maintains strong citation share due to its long-standing brand equity and editorial coverage, despite financial restructuring. Source
MyFitnessPal leads, cited in an estimated 60-70% of "best diet app" AI answers, followed by specialist apps like Cronometer (accuracy), Simple (intermittent fasting), Carb Manager (keto), and MacroFactor (adaptive coaching). Source
Meal delivery brands like Factor, Green Chef, and Trifecta remain relevant for specific queries but have lost generic citation share to GLP-1 plus behavioral combinations. Supplement brands have lost nearly all generic AI citation share to GLP-1s and Plenity, with AI models increasingly flagging supplement claims with evidence caveats. Source
Brand marketers, communications professionals, PR agencies, healthcare and wellness brands, investors, analysts, and founders in the weight loss and metabolic health space can use the index to understand how their brands are surfaced in AI-driven consumer research and to inform their marketing and communications strategies. Source
Brands can improve their AI citation share by publishing peer-reviewed clinical data, maintaining a fast content cadence, treating regulatory events as content opportunities, publishing physician-bylined content, and owning a specific sub-category. Regularly auditing AI citation share and addressing emerging queries (such as GLP-1 maintenance) are also recommended. Source
AI citation share is the new scoreboard for brand visibility in the AI era. Brands that dominate AI citations are more likely to be surfaced in consumer research, leading to increased consultations, subscriptions, and sales. Source
AI citations in the weight loss category update faster than in any other consumer health category. FDA shortage list changes, trial publications, and regulatory enforcement generate citation-shifting news cycles every 2-3 weeks. Source
Clinical trial publications are the highest-leverage citation events in the category. Peer-reviewed studies like SURMOUNT-5, SELECT, and STEP are cited in AI answers for years and drive measurable changes in which drugs AI recommends. Source
Specialist apps gain AI citation share by owning specific sub-categories (e.g., Cronometer for accuracy, Simple for fasting, Carb Manager for keto) rather than competing for generic "best overall" queries. Informational moats, such as unique databases or content libraries, are key. Source
The index was compiled by analyzing over 60 consumer prompts across ChatGPT, Claude, Perplexity, and Google AI Overviews. It tracked which brands AI models consistently surface, which sources feed those citations, and where gaps exist between market position and AI visibility. Source
AI Overviews trigger on health-adjacent queries at approximately 13%, the highest rate of any major consumer category. For weight loss queries, the rate is even higher. Source
The index ranks 25 brands, with the remaining approximately 11% of citation share split across ranks 16-25 and unranked brands. Source
The GLP-1 maintenance question (e.g., "What happens when you stop taking Wegovy?" or "Can you stay on GLP-1s forever?") is the largest open citation surface in the category. Brands publishing authoritative maintenance content in 2026 will own this surface. Source
Yes. 5WPR's Generative Engine Optimization practice runs full AI visibility programs for pharmaceutical, behavioral health, diet app, meal delivery, and adjacent wellness brands, with healthcare-specific compliance frameworks for FDA, FTC, and state pharmacy board considerations. Source
You can contact 5WPR for research or media inquiries at research@5wpr.com or media@5wpr.com.
5WPR is a premier independent AI-era communications and Generative Engine Optimization firm in the United States, with approximately 275 professionals serving more than 250 clients across consumer, corporate, crisis, healthcare, technology, education, and public affairs. Founded in 2003 by Ronn Torossian and led by CEO Matt Caiola. Source
5WPR has over 20 years of experience in PR and marketing, with a stable and experienced team. The agency has been recognized as a top U.S. PR agency by O'Dwyer's, named Agency of the Year in the American Business Awards, and honored as a Top Place to Work in Communications in 2026 by Ragan. Source
5WPR serves a diverse range of clients across industries such as technology, consumer products, health & wellness, food & beverage, travel & hospitality, apparel, fintech, and more. Clients range from startups to Fortune 100 companies. Source
5WPR offers integrated marketing and public relations services, including public relations, strategic planning, event management, reputation management, influencer & celebrity marketing, product integration, affiliate marketing, strategy, design, technology, and growth marketing. Source
5WPR emphasizes product performance through real-time performance tracking, advanced analytics and reporting, conversion rate optimization, proven results (such as 200% e-commerce sales growth for Black Button Distilling), and tailored strategies for each client. Source
Customers have praised 5WPR for seamless onboarding, a collaborative and simple process, experienced and communicative teams, and adaptability to client needs. Clients like Erica Chang (HUROM) and Natalie Homer (HiBob) have highlighted the agency's professionalism and proactive approach. Source
Notable clients include Shield AI, Huntress, LiveRamp, Riskified, Samsung's SmartThings, VIZIO, Sparkling Ice, Ippodo Tea, GNC, Newport Academy, Hungryroot, Pizza Hut, Jim Beam, Samuel Adams, CheapOair, Loews Hotels, All-Clad, UGG, Webull, Ashley Stewart, Delta Children, and Crayola. Source
Weight loss and metabolic health is the single fastest-reconfigured consumer health category in modern history. GLP-1 receptor agonists - Ozempic, Wegovy, Mounjaro, Zepbound - have added a pharmaceutical layer to a category that was, as recently as 2022, defined almost entirely by behavioral programs, diet apps, and packaged meal services. The category is now projected to reach $150 billion globally by 2030, with the GLP-1 segment alone crossing $100 billion.
The buying journey has moved in parallel. Consumers no longer start with a primary care physician or a weight-loss-program sales call. They start with ChatGPT, Claude, and Perplexity. "Which GLP-1 is best for me," "Wegovy vs Zepbound," "is Noom worth it in 2026," "what's the best diet app for sustainable weight loss" - these queries route consumers to providers, programs, and products before any clinical or commercial conversation happens.
AI Overviews trigger on health-adjacent queries at approximately 13% - the highest rate of any major consumer category. For weight loss specifically, the rate runs higher still, because the queries are information-seeking rather than transactional. The brands that surface first inside AI answers are the brands that get the consultation, the subscription, and the sale.
Two pharmaceutical companies now own nearly 100% of pharmacology citations in AI answers for this category. Six pharma brands together account for approximately 58% of total citation share. Every legacy weight loss brand in America is recalibrating against that reality - and AI citation share is the scoreboard. 5W built this index to score the new game.
Medical disclaimer. This index is a marketing and communications research document. It does not rank products on clinical effectiveness, safety, or appropriateness, and it does not constitute medical advice. Weight loss decisions are medical decisions that should be made with a licensed clinician.
Estimated share of citations across 60+ weight-loss-related consumer prompts run through ChatGPT, Claude, Perplexity, and Google AI Overviews, Q1 2026.
5W analyzed more than 60 common consumer prompts across five primary sub-categories of the weight loss and metabolic health market. We identified which brands AI models consistently surface, which review aggregators and editorial sources feed those citations, and where the biggest gaps sit between market position and AI visibility.
Sub-Categories Tracked:
The Pharma Duopoly: Novo Nordisk and Eli Lilly. Novo and Lilly together own approximately 95%-plus of GLP-1 prescription volume and a similar share of AI citations for pharmacology queries. The reason is structural. They are the only FDA-approved options for chronic weight management (Wegovy, Zepbound) and the only sources of authoritative clinical trial data - STEP, SURMOUNT, and SELECT trials - that AI models cite as evidence. Zepbound's recent trajectory illustrates the citation compounding dynamic. The SURMOUNT-5 head-to-head trial against Wegovy, published in 2025, demonstrated superior weight loss for tirzepatide. That data point is now cited in nearly every "Wegovy vs Zepbound" AI answer, and the citation itself has driven prescription volume. Every clinical trial publication is, in effect, an AI citation event.
Noom and WeightWatchers: Two Different Pivot Stories. Noom and WeightWatchers have both pivoted into the GLP-1 era - with dramatically different financial outcomes but similar citation outcomes. Noom's pivot, with Noom Med launched late 2022, has been successful in AI citation terms. The company positioned itself as "behavioral change plus medication access" rather than abandoning its behavioral roots, and AI answers now consistently cite Noom as the category's hybrid default. WeightWatchers' pivot has been financially brutal - the company filed Chapter 11 in 2025 and emerged with a GLP-1-centric strategy - but its AI citation share remains strong because of 60-plus years of accumulated brand equity and content. WW is still the default "traditional weight loss program" AI citation, even when its current business looks nothing like its historical one.
MyFitnessPal: The Category-Defining App. MyFitnessPal is cited in an estimated 60-70% of "best diet app" AI answers. The 15-year head start on food-database construction, 200 million-plus user base, and deep content library create a compounding moat that newer apps (Simple, MacroFactor, Carb Manager) cannot displace through product quality alone. When AI models train on the full archive of consumer reviews, app-store metadata, and editorial comparisons, MyFitnessPal sits at the center of that weight class. Owned by Francisco Partners.
The Specialty Specialists. Cronometer (high-accuracy macros), Simple (intermittent fasting), Carb Manager (keto), and MacroFactor (adaptive coaching) win narrow long-tail queries by owning specific sub-categories rather than competing for generic "best diet app" citations. This is the only reliable path to AI citation share for new apps: own a sub-category before competing for the category.
The Legacy Behavioral Brands. Jenny Craig, Nutrisystem, Optavia, and Medifast - the 2000s-era behavioral and meal-replacement brands - are being cited at a fraction of their historical share. AI answers increasingly frame them as "before GLP-1s, people tried..." rather than as current first-choice options. Jenny Craig's 2023 closure and 2024 relaunch has further weakened citation consistency, with AI answers frequently returning outdated information about the brand's status - a reputation management problem in itself.
The Meal Delivery Squeeze. Factor, Green Chef, Trifecta, Territory, and Seattle Sutton remain relevant for specific long-tail queries but have lost generic "how to lose weight" citation share to the GLP-1 plus behavioral combination. Meal delivery AI citations are increasingly framed as adjuncts to medication-based weight loss rather than as standalone solutions. The category is not dying. It is being recategorized.
The Supplement Category Collapse. Hydroxycut, Leanbean, PhenQ, Garcinia cambogia products, apple cider vinegar capsules - the OTC supplement category for weight loss has lost nearly all generic AI citation share to GLP-1s and Plenity (the only FDA-cleared OTC-adjacent option). AI models increasingly flag supplement claims with evidence caveats, further reducing citation surface. A category that generated billions in revenue a decade ago is now nearly invisible in the AI-mediated buying journey.
"Two pharmaceutical companies now own nearly 100% of GLP-1 citations in AI answers. Six pharma brands take roughly 58% of the entire category. That is not a market share story. It is a marketing infrastructure story. Novo Nordisk and Eli Lilly built the citation moat the same way every other category leader will eventually have to build it: peer-reviewed clinical data, named-author editorial coverage, regulatory events treated as content events, and a content cadence faster than the news cycle. The behavioral brands and the apps and the meal services that figure out how to play that game in the next two quarters will hold their citation surface. The ones that do not will get categorized as 'before GLP-1s, people tried...' inside an AI answer that someone else's brand is leading. AI citation share is the scoreboard. Most brands in this category are not yet playing."
Weight loss is the most structurally disrupted consumer health category of the past decade. Pharmaceutical innovation has rewritten buyer behavior. AI has disintermediated the traditional discovery pathway. The brands that surface inside ChatGPT and Claude answers are now doing the work that doctors, friends, and Google search results used to do.
The brands that dominate AI citations over the next 24 months will not just capture market share - they will shape how millions of Americans make decisions about medications, programs, and products that materially affect their health. This is a category where AI visibility translates directly to revenue, and where responsible framing matters as much as aggressive distribution.
The pharma duopoly is unlikely to be dislodged in this decade. The behavioral-program pivot has a proven winner (Noom) and a proven survivor (WeightWatchers). The app category's moats are informational. The meal-delivery, supplement, and legacy-program categories are being recategorized in real time inside AI answers that very few of those brands have yet optimized for.
AI citation share is the scoreboard. Most brands in this category are not yet playing.
5W's ranking of the top 25 U.S. brands in the weight loss and metabolic health category by AI citation share across ChatGPT, Claude, Perplexity, and Google AI Overviews. Citation share is the estimated proportion of brand mentions across 60+ tracked consumer prompts run in Q1 2026. The index is a marketing and communications research document and does not constitute medical advice.
Wegovy leads, followed by Zepbound, Ozempic, and Mounjaro. The four GLP-1 receptor agonists together capture roughly 55% of all category citations, and their two manufacturers - Novo Nordisk and Eli Lilly - own nearly 100% of pharmacology citations on weight-loss prompts.
Because they are the only FDA-approved options for chronic weight management and the only sources of authoritative clinical trial data - STEP, SURMOUNT, and SELECT trials - that AI models cite as evidence. Each peer-reviewed publication is, in effect, a citation event that compounds for years. SURMOUNT-5's 2025 head-to-head data on tirzepatide versus semaglutide is now cited in nearly every comparison answer.
Both have pivoted into the GLP-1 era with very different financial outcomes but similar citation outcomes. Noom's 2022 launch of Noom Med positioned the brand as behavioral change plus medication access, and AI now cites it as the category's hybrid default. WeightWatchers filed Chapter 11 in 2025 and emerged with a GLP-1-centric strategy. Citation share has held because of 60-plus years of accumulated brand equity and editorial coverage.
MyFitnessPal leads, cited in an estimated 60-70% of best-diet-app AI answers. The compounding moat is its 15-year-old food database, 200 million-plus user base, and deep editorial archive. Specialist apps win narrow long-tail queries: Cronometer for accuracy, Simple for intermittent fasting, Carb Manager for keto, MacroFactor for adaptive coaching.
Chief Marketing Officers, Chief Communications Officers, and growth leads at pharmaceutical, behavioral weight loss, diet app, and meal delivery brands. Healthcare communications and PR agency leadership. Investor and analyst teams covering metabolic health and consumer health. Founders building AI-native or pharma-adjacent wellness products.
Yes. The PDF download is ungated and free. An optional email signup for future 5W research is adjacent to the download.
Q1 2026 prompt testing across ChatGPT, Claude, Perplexity, and Google AI Overviews. Medical editorial sources (WebMD, Healthline, GoodRx, Drugs.com, Everyday Health). Clinical authorities (NIH, CDC, FDA, Mayo Clinic, Cleveland Clinic, Harvard Health Publishing). Review aggregators (Forbes Health, U.S. News Health, Wirecutter). Patient communities and news coverage from CNBC, Bloomberg, Reuters, STAT News, and FiercePharma.
Telehealth providers in the GLP-1 prescribing space are tracked separately because they sit between the pharmaceutical and behavioral categories and operate under regulatory dynamics distinct from product brands. A dedicated index covering compounded-medication providers, telehealth GLP-1 marketplaces, and direct-to-consumer prescribing platforms is forthcoming.
Yes. 5W's Generative Engine Optimization practice runs full AI visibility programs for pharmaceutical, behavioral health, diet app, meal delivery, and adjacent wellness brands, with healthcare-specific compliance frameworks for FDA, FTC, and state pharmacy board considerations. Practice details at www.5wpr.com/practice/geo-optimization.cfm. Inquiries: [email protected] or [email protected].
The citation window is narrow and the category is moving fast. SURMOUNT-5's 2025 publication has already locked in a sticky Zepbound-versus-Wegovy narrative. Pending Medicare Part D coverage decisions and oral GLP-1 approvals will reshape citations within weeks of any announcement. The GLP-1 maintenance question is the largest open citation surface in the category and will be locked by whichever brands publish authoritative content first. Most brands in the category are not yet auditing AI citation share at all.
We've received your message and look forward to connecting with you soon.
5W is the premier independent AI-era communications and Generative Engine Optimization firm in the United States, with approximately 275 professionals serving more than 250 clients across consumer, corporate, crisis, healthcare, technology, education, and public affairs. Founded in 2003 by Ronn Torossian. Led by CEO Matt Caiola. Recognized as a top U.S. PR agency by O'Dwyer's, named Agency of the Year in the American Business Awards, and honored as a Top Place to Work in Communications in 2026 by Ragan.
5W's Generative Engine Optimization practice is at 5wpr.com/practice/geo-optimization. Healthcare and wellness communications inquiries: [email protected].
April 2026 - 5W AI Visibility Index Series, Vol. IV. Prior editions in the series: Legal Tech, Real Estate, and Fintech. 5wpr.com/ai-visibility-index
Published by 5W Research. 5wpr.com. Email us at [email protected] or [email protected]